Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-0482 + pembrolizumab + nab-paclitaxel + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen of four agents: - **MK-0482**: a monoclonal antibody targeting leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), inhibiting its immunosuppressive action and promoting antitumor immune activity. - **Pembrolizumab**: a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, blocking PD-1-mediated immunoinhibition and activating T-cell antitumor responses. - **Nab-paclitaxel**: an albumin-bound formulation of paclitaxel, a microtubule inhibitor that blocks mitosis and triggers apoptosis, formulated for improved tumor delivery. - **Gemcitabine**: a nucleoside analog chemotherapeutic, inhibiting DNA synthesis and mainly used for solid tumors. This combination is in development for the treatment of advanced/metastatic solid tumors, such as pancreatic ductal adenocarcinoma, glioblastoma, and other solid cancers, being evaluated for safety, tolerability, and preliminary efficacy in Phase 1 clinical trials.
- Other names
- MK 0482MK0482MK-0482pembrolizumabAbraxanegemcitabine hydrochloride
02
Targets
DNALILRB4PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MK-0482 + pembrolizumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-0482 + pembrolizumab + nab-paclitaxel + gemcitabine.